Clinical Trials, Phase I as Topic
"Clinical Trials, Phase I as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
Descriptor ID |
D017321
|
MeSH Number(s) |
E05.318.760.250.500.200 N05.715.360.775.088.500.200 N06.850.520.450.250.250.200
|
Concept/Terms |
Microdosing Trials, Human- Microdosing Trials, Human
- Human Microdosing Trial
- Microdosing Trial, Human
- Trial, Human Microdosing
- Trials, Human Microdosing
- Human Microdosing Trials
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase I as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase I as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase I as Topic" by people in this website by year, and whether "Clinical Trials, Phase I as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 2 | 3 |
1995 | 2 | 3 | 5 |
1996 | 0 | 2 | 2 |
1997 | 2 | 2 | 4 |
1998 | 0 | 2 | 2 |
1999 | 1 | 2 | 3 |
2000 | 1 | 0 | 1 |
2001 | 2 | 2 | 4 |
2002 | 0 | 2 | 2 |
2003 | 3 | 3 | 6 |
2004 | 2 | 3 | 5 |
2005 | 2 | 2 | 4 |
2006 | 3 | 0 | 3 |
2007 | 4 | 2 | 6 |
2008 | 3 | 0 | 3 |
2009 | 1 | 0 | 1 |
2010 | 1 | 3 | 4 |
2011 | 3 | 3 | 6 |
2012 | 2 | 3 | 5 |
2013 | 1 | 3 | 4 |
2014 | 1 | 7 | 8 |
2015 | 4 | 1 | 5 |
2016 | 4 | 2 | 6 |
2017 | 1 | 1 | 2 |
2018 | 1 | 2 | 3 |
2019 | 2 | 0 | 2 |
2020 | 0 | 1 | 1 |
2022 | 0 | 3 | 3 |
2023 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase I as Topic" by people in Profiles.
-
Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
-
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Adv Sci (Weinh). 2023 08; 10(23):e2300445.
-
Host happy hour: Phage cocktail targets IBD-associated microbes. Cell Host Microbe. 2022 10 12; 30(10):1352-1353.
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60.
-
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leuk Lymphoma. 2022 Oct; 63(10):2413-2421.
-
T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1. Front Immunol. 2020; 11:575977.
-
Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Hum Gene Ther. 2020 10; 31(19-20):1132-1139.
-
The i3+3 design for phase I clinical trials. J Biopharm Stat. 2020 03; 30(2):294-304.
-
R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials. J Biopharm Stat. 2019; 29(3):411-424.
-
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491.